Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365736/ https://www.ncbi.nlm.nih.gov/pubmed/32678432 http://dx.doi.org/10.1084/jem.20201342 |
_version_ | 1783560092304539648 |
---|---|
author | Koenig, Lars M. Boehmer, Daniel F.R. Metzger, Philipp Schnurr, Max Endres, Stefan Rothenfusser, Simon |
author_facet | Koenig, Lars M. Boehmer, Daniel F.R. Metzger, Philipp Schnurr, Max Endres, Stefan Rothenfusser, Simon |
author_sort | Koenig, Lars M. |
collection | PubMed |
description | An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation. |
format | Online Article Text |
id | pubmed-7365736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-73657362020-08-07 Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19 Koenig, Lars M. Boehmer, Daniel F.R. Metzger, Philipp Schnurr, Max Endres, Stefan Rothenfusser, Simon J Exp Med Viewpoint An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation. Rockefeller University Press 2020-07-17 /pmc/articles/PMC7365736/ /pubmed/32678432 http://dx.doi.org/10.1084/jem.20201342 Text en © 2020 Koenig et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Viewpoint Koenig, Lars M. Boehmer, Daniel F.R. Metzger, Philipp Schnurr, Max Endres, Stefan Rothenfusser, Simon Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19 |
title | Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19 |
title_full | Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19 |
title_fullStr | Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19 |
title_full_unstemmed | Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19 |
title_short | Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19 |
title_sort | blocking inflammation on the way: rationale for cxcr2 antagonists for the treatment of covid-19 |
topic | Viewpoint |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365736/ https://www.ncbi.nlm.nih.gov/pubmed/32678432 http://dx.doi.org/10.1084/jem.20201342 |
work_keys_str_mv | AT koeniglarsm blockinginflammationonthewayrationaleforcxcr2antagonistsforthetreatmentofcovid19 AT boehmerdanielfr blockinginflammationonthewayrationaleforcxcr2antagonistsforthetreatmentofcovid19 AT metzgerphilipp blockinginflammationonthewayrationaleforcxcr2antagonistsforthetreatmentofcovid19 AT schnurrmax blockinginflammationonthewayrationaleforcxcr2antagonistsforthetreatmentofcovid19 AT endresstefan blockinginflammationonthewayrationaleforcxcr2antagonistsforthetreatmentofcovid19 AT rothenfussersimon blockinginflammationonthewayrationaleforcxcr2antagonistsforthetreatmentofcovid19 |